

## Supplemental Information

### SUPPLEMENTAL REFERENCES

- World Health Organization. Combating hepatitis B and C to reach elimination by 2030. Available at: <https://www.who.int/hepatitis/publications/hep-elimination-by-2030-brief/en/>. Accessed August 28, 2023
- Department of Health and Human Services. Viral hepatitis national strategic plan for the United States: a roadmap to elimination (2021-2025). Available at: <https://www.hhs.gov/sites/default/files/Viral-Hepatitis-National-Strategic-Plan-2021-2025.pdf>. Accessed October 16, 2023
- Prasad M, Saade GR, Clifton RG, et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Risk factors for perinatal transmission of hepatitis C virus. *Obstet Gynecol*. 2023;142(3):449–456
- Hall EW, Panagiotakopoulos L, Wester C, Nelson N, Sandul AL. Cost-effectiveness of strategies to identify children with perinatally acquired hepatitis C infection. *J Pediatr*. 2023;258:113409
- Moore JD, Nguyen UDT, Ojha RP, Griner SB, Thompson EL. Physician-level determinants of HCV screening during pregnancy in a U.S. sample [published online ahead of print July 16, 2023]. *Arch Gynecol Obstet*.
- American Association for the Study of Liver Diseases/Infectious Diseases Society of America. HCV in pregnancy. Available at: <https://www.hcvguidelines.org/unique-populations/pregnancy>. Accessed August 30, 2023
- Jonas MM, Rhee S, Kelly DA, et al. Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in children with chronic HCV: part 2 of the DORA Study. *Hepatology*. 2021;74(1):19–27
- Jonas MM, Romeri R, Sokal E, et al. Safety and efficacy of sofosbuvir/velpatasvir in pediatric patients 6 to <18 years old with chronic hepatitis C infection. Presented at: The Liver Meeting; 2019; Boston, MA. Abstract 748
- Jonas MM, Squires RH, Rhee SM, et al. Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in adolescents with chronic hepatitis C virus: part 1 of the DORA Study. *Hepatology*. 2020;71(2):456–462
- Lampe MA, Nesheim SR, Oladapo KL, Ewing AC, Wiener J, Kourtis AP. Achieving elimination of perinatal HIV in the United States. *Pediatrics*. 2023;151(5):e2022059604
- Schillie S, Walker T, Veselsky S, et al. Outcomes of infants born to women infected with hepatitis B. *Pediatrics*. 2015;135(5):e1141–e1147
- Barritt AS IV, Jhaveri R. Treatment of hepatitis C during pregnancy—weighing the risks and benefits in contrast to HIV. *Curr HIV/AIDS Rep*. 2018;15(2):155–161
- Yee LM, Simon MA, Grobman WA, Rajan PV. Pregnancy as a “golden opportunity” for patient activation and engagement. *Am J Obstet Gynecol*. 2021;224(1):116–118
- Jhaveri R, Yee LM, Antala S, Murphy M, Grobman WA, Shah SK. Responsible inclusion of pregnant individuals in eradicating HCV. *Hepatology*. 2021;74(3):1645–1651
- Trooskin S, Jhaveri R. Conversations with the editors: hepatitis C virus—where are we now and where do we go from here? *Clin Ther*. 2020;42(8):1425–1432.
- Jhaveri R. We need a new national strategy for hepatitis C virus screening. *Pediatrics*. 2020;145(3):e20193060
- Jhaveri R. Elimination means everyone: targeting hepatitis C in infants and pregnant patients. *Clin Infect Dis*. 2023;76(5):920–922